BofA Global Research raised AstraZeneca's 2025 EPS forecast to $9.07, up from $8.96, expecting Q1 revenue of $14 billion, an 11% year-over-year rise, and EPS of $2.25.
AstraZeneca's stock rose 1-2% after President Trump's tariff exemption for pharmaceuticals, peaking at 11,430p, offering temporary relief amid market declines and tariff concerns.
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.